Inovio Pharmaceuticals (MEX:INO) Other Long-Term Liabilities: MXN0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:INO Inovio Pharmaceuticals Inc MEX:INO
39 GF Score
Price MXN21.00
GF Value MXN3.68
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Inovio Pharmaceuticals Other Long-Term Liabilities?

Inovio Pharmaceuticals MEX:INO -0.19% 39 Other Long-Term Liabilities is MXN0.00 Mil as of Jun. 2026. GuruFocus rates MEX:INO with a GF Score™ of 39/100 and a GF Value™ of MXN3.68 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Inovio Pharmaceuticals's other long-term liabilities for the quarter that ended in Jun. 2026 was MXN0.00 Mil.

Inovio Pharmaceuticals's quarterly other long-term liabilities stayed the same from Dec. 2025 (MXN-0.00 Mil) to Mar. 2026 (MXN-0.00 Mil) but then increased from Mar. 2026 (MXN-0.00 Mil) to Jun. 2026 (MXN0.00 Mil).

Inovio Pharmaceuticals's annual other long-term liabilities declined from Dec. 2023 (MXN0.00 Mil) to Dec. 2024 (MXN-0.02 Mil) but then increased from Dec. 2024 (MXN-0.02 Mil) to Dec. 2025 (MXN-0.00 Mil).

Inovio Pharmaceuticals Other Long-Term Liabilities Related Terms

Inovio Pharmaceuticals Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Inovio Pharmaceuticals's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inovio Pharmaceuticals Other Long-Term Liabilities Chart

Inovio Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.31 0.02 0.00 -0.02 -0.00

Inovio Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.00 -0.00 0.00
MEX:INO
39GF Score
Inovio Pharmaceuticals Inc MEX:INO
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inovio Pharmaceuticals Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of MXN0.00 Mil mean?
Inovio Pharmaceuticals (MEX:INO) has a Other Long-Term Liabilities of MXN0.00 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Inovio Pharmaceuticals and its competitors.
Is Inovio Pharmaceuticals' Other Long-Term Liabilities too high?
Inovio Pharmaceuticals' current Other Long-Term Liabilities is MXN0.00 Mil. Overall, Inovio Pharmaceuticals has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inovio Pharmaceuticals' Other Long-Term Liabilities compare to TELO and ELTX?
Inovio Pharmaceuticals' Other Long-Term Liabilities of MXN0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Inovio Pharmaceuticals and its competitors. Inovio Pharmaceuticals's current Other Long-Term Liabilities is MXN0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inovio Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Inovio Pharmaceuticals (MEX:INO) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN3.68, compared to a current price of MXN21.00 — trading 470.7% above its estimated fair value. The current Other Long-Term Liabilities is MXN0.00 Mil. Inovio Pharmaceuticals' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Inovio Pharmaceuticals (MEX:INO), the current Other Long-Term Liabilities is MXN0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inovio Pharmaceuticals (MEX:INO) Overvalued in 2026?

Based on GuruFocus' analysis, Inovio Pharmaceuticals stock appears to be overvalued. The current stock price of MXN21.00 is trading 470.7% above its estimated GF Value™ of MXN3.68. GuruFocus considers Inovio Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for MEX:INO:

  • Other Long-Term Liabilities: MXN0.00 Mil
  • GF Value™: MXN3.68 vs. price of MXN21.00 (470.7% above fair value)
  • GF Score™: 39/100 with 4 warning signs

No single metric tells the full story. See the MEX:INO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Inovio Pharmaceuticals Business Description

Other Exchanges INO:USA0A43:UKGBM:Germany
Address 660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
39GF Score

Get the complete analysis for MEX:INO

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN21.00
Price
MXN3.68
GF Value